EFFECT OF ESCITALOPRAM ON GLYCAEMIC CONTROL IN TYPE 2 DIABETES MELLITUS PATIENTS WITH DEPRESSION

Laxmi Shrestha¹, Anita Adhikari², Sandip Subedi², Buddhi Raj Pokhrel³, Amit Kumar Shrivastava¹, Bishal Joshi⁴, Pradip Chhetri⁵

¹Department of Pharmacology, Universal College of Medical Sciences, Ranigaon, Bhairahawa, Nepal
²Department of Psychiatry, Universal College of Medical Sciences, Ranigaon, Bhairahawa, Nepal
³Department of Biochemistry, Universal College of Medical Sciences, Ranigaon, Bhairahawa, Nepal
⁴Department of Physiology, Universal College of Medical Sciences, Ranigaon, Bhairahawa, Nepal
⁵Department of Community Medicine, Universal College of Medical Sciences, Ranigaon, Bhairahawa, Nepal

INTRODUCTION

Diabetes mellitus (DM) is a metabolic disorder characterized by hyperglycemia, insulin resistance, defects in insulin secretion, insulin action or both.¹ Type 2 diabetes mellitus is more common than type 1 diabetes mellitus and is associated with comorbid conditions like hypertension, dyslipidemia, depression.²

Various studies have shown an increased incidence of depression in patients with type 2 diabetes mellitus.²,³ Depression is the most common mental disorder that occurs in all ages worldwide. There is a high prevalence of depression with or without comorbid anxiety among patients of DM.² Diabetes associated with depression can aggravate both the symptoms of depression as well as diabetes-associated complications.⁴ The patients with co-existent diabetes and depression have poorer health outcomes such as poor symptom control, poor glycemic control, more frequent microvascular and macrovascular complications, increased loss of work and higher mortality risk compared to patients with diabetes alone.⁵

Selective Serotonin Reuptake Inhibitors (SSRIs) like Fluoxetine, Escitalopram and Sertraline are commonly prescribed to treat depression associated with diabetes. Among these SSRIs, Escitalopram has high selectivity for the serotonin transporter and has minimal inhibitory effect on cytochrome P-450 2D6 and 3A4 isoenzymes with no risk of hyper or hypoglycemia or weight gain.⁶,⁷

In the present study, we aimed to observe the effect of Escitalopram in achieving glycemic control in type 2 DM patients with depression.

METHODS

This is a longitudinal follow up study conducted in psychiatry outpatient department (OPD) of Universal College of Medical Sciences (UCMS), Bhairahawa after the approval of the Institutional Review Committee (IRC) of UCMS (IRC No. 189/19).

Sample size was calculated as, n= \( \frac{Z^2pq}{d^2} = 137 \)

Where,

- \( p = \) prevalence of type 2 DM in Nepal = 0.084
- \( q = 1-p = 0.916 \)
- \( d = \) allowable error at 8%
- \( z = \) level of significance at 5%

Results: After the treatment with escitalopram, there was significant (p<0.05) reduction in fasting and postprandial blood glucose level in subsequent weeks compared to baseline values. The fasting and postprandial blood glucose levels were measured at baseline, two weeks, four weeks, and six weeks interval, respectively, using the automated analyzer.

Conclusions: Treatment with escitalopram showed a favorable glycemic profile in type 2 DM patients with depression.
All patients diagnosed with Type 2 DM visiting the internal medicine out-patient department (OPD) of Universal College of Medical Sciences (UCMS), Bhairahawa, Nepal, from September 2019 to March 2020 were referred to psychiatric OPD for evaluation of depression. Informed written consent was obtained from the patients prior to the study. Patients with a history of prior psychiatric illness and/or medication were excluded. Patient Health Questionnaire -9 (PHQ-9) was used for the assessment of depression by the consultant psychiatrist. A score of ≥ 5 was considered as depression. A total of 137 participants were divided into two groups. Group 1 included type 2 diabetic patients with depression (n=37) and group 2 without depression (n=100). Escitalopram 10 mg daily was prescribed for group 1 patients only, keeping the management of diabetes mellitus unchanged for all. The comorbidity conditions identified was referred to respective consultant for further evaluation.

The fasting and postprandial (PP) blood glucose levels were measured at baseline (prior to ESC treatment in group 1), two weeks, four weeks, and six weeks interval, respectively, using the automated analyzer (Huma Star 600, Germany) in central laboratory of UCMS, Bhairahawa. The study Proforma was filled which included socio-demographic parameters, duration of type 2 DM, types of antidiabetic treatment, and co-morbidities (hypertension, Chronic Kidney disease, Diabetic foot, thyroid disorders, and others) present.

Data were entered in Microsoft Excel and analyzed using a statistical package for social sciences (SPSS version 16). Shapiro-Wilk test was done to assess the normality of distribution of the numerical variables. Non-parametric analyses were performed as the distributions were skewed. The Wilcoxon Signed Rank Test was performed to compare blood glucose levels of subsequent weeks with baseline values. A p-value of <0.05 was considered statistically significant.

RESULTS

A total of 137 patients diagnosed with type 2 diabetes mellitus were studied, where 37 patients were diagnosed as having depression. Hence, the prevalence of depression in type 2 DM was 27%. Table 1 shows the distribution of socio-demographic variables of the study group. The number of female patients in group 1 was significantly higher (p = 0.019) as compared to males. However, we did not find any significant difference in the age-wise distribution between the two groups.

Table 1: Socio-demographic characteristics of the study group

| Variable            | Total study population (N=137) | Group 1 (N=37) | Group 2 (N=100) | p-value |
|---------------------|--------------------------------|----------------|-----------------|---------|
| Age Group (Years)   |                                |                |                 |         |
| 25-40               | 17 (12.4%)                     | 4 (10.8%)      | 13 (13%)        | 0.087   |
| 41-60               | 80 (58.4%)                     | 27 (73%)       | 53 (53%)        |         |
| >60                 | 40 (29.2%)                     | 6 (16.2%)      | 34 (34%)        |         |
| Sex                 |                                |                |                 |         |
| Male                | 66 (48.2%)                     | 10 (27%)       | 56 (56%)        | 0.019   |
| Female              | 71 (51.8%)                     | 27 (73%)       | 44 (44%)        |         |
| Marital status      |                                |                |                 |         |
| Married             | 132 (96.4%)                    | 35 (94.6%)     | 97 (97%)        | 0.612 a |
| Unmarried           | 5 (3.6%)                       | 2 (5.4%)       | 3 (3%)          |         |
| Education           |                                |                |                 |         |
| Illiterate          | 52 (38%)                       | 17 (46%)       | 35 (35%)        | 0.085   |
| Primary Level       | 61 (44.5%)                     | 13 (35.1%)     | 48 (48%)        |         |
| Secondary Level     | 16 (11.7%)                     | 3 (8.1%)       | 13 (13%)        |         |
| Higher secondary & above | 8 (5.8%) | 4 (10.8%) | 4 (4%) |         |
| Occupation          |                                |                |                 |         |
| Housewife           | 55 (40.1%)                     | 21 (56.8%)     | 34 (34%)        | 0.110   |
| Service             | 20 (14.6%)                     | 5 (13.5%)      | 15 (15%)        |         |
| Business            | 10 (7.3%)                      | 2 (5.4%)       | 8 (8%)          |         |
| Farmer              | 30 (21.9%)                     | 5 (13.5%)      | 25 (25%)        |         |
| Others              | 22 (16.1%)                     | 4 (10.8%)      | 18 (18%)        |         |
| Socioeconomic status|                                |                |                 |         |
| High                | 13 (9.5%)                      | 2 (5.4%)       | 11(11%)         | 0.554   |
| Middle              | 111 (81.0%)                    | 33 (89.2%)     | 78 (78%)        |         |
| Low                 | 13 (9.5%)                      | 5 (4.4%)       | 11 (11%)        |         |

p- values obtained from Chi-square analysis. a= Fischer’s Exact test. p-values <0.05 considered statistically significant, and are expressed in bold typing.

Table 2 shows the diabetic characteristics, duration, management, and co-morbidities present in the study population. The majority of the patients had uncontrolled DM in both groups (73% in Group 1; 67% in Group 2) and were under Oral Hypoglycemic agents for the treatment (67.6% in Group 1; 84% in Group 2).

Figure 1 represents the baseline blood glucose level (both fasting and PP) in the study group. The baseline median values of
between the treatment groups in different timelines (baseline, 2, 4, and 6 weeks), respectively, as shown in Table 3. Forty participants (five from Group 1, 35 from Group 2) were lost during follow-up; hence the comparison was made in the remaining study population.

Both group 1 and group 2 patients were under antidiabetic treatment for at least five years. However, the baseline median glucose levels (both fasting and PP) of the Group 1 patients were higher than Group 2 patients. After the treatment of group 1 patients with ESC, this difference was minimized, especially in the 4th and 6th weeks (Table 3). This indicates that antidiabetic drugs alone could reduce blood glucose levels effectively in Group 2 patients, but not in Group 1 patients. However, after the ESC administration, both groups had similar glycemic control, mainly in the 6th week.

Figure 1: Comparison of baseline blood glucose levels (Fasting and PP) between the groups with depression and without depression

Table 2: Diabetic characteristics of study population

| Variables          | Total Study Population (N = 137) | Group 1 (N = 37) | Group 2 (N = 100) | p-value |
|--------------------|----------------------------------|------------------|-------------------|---------|
| Type 2 DM          | Controlled DM                    | 42 (30.7%)       | 10 (27%)          | 33 (33%) | 0.817   |
|                    | Uncontrolled DM                  | 95 (69.3%)       | 27 (73%)          | 67 (67%) |         |
| Duration Type 2 DM | ≤ 5                               | 85 (62.0%)       | 17 (46%)          | 68 (68%) | 0.087   |
| (Years)            | 10                                | 24 (17.5%)       | 7 (19%)           | 17 (17%) |         |
|                    | >15                               | 13 (9.5%)        | 7 (19%)           | 6 (6%)   |         |
| Diabetes treatment | OHA                              | 109 (79.6%)      | 25 (67.6%)        | 84 (84%) | 0.054   |
|                    | Insulin                           | 28 (20.4%)       | 12 (32.4%)        | 16 (16%) |         |
| Co-morbidities     | Present                           | 84 (61.3%)       | 23 (27.4%)        | 61 (72.6%) | 0.90   |
|                    | Absent                            | 53 (38.7%)       | 14 (27.4%)        | 39 (73.6%) |         |

Abbreviations: DM-Diabetes Mellitus; OHA- Oral Hypoglycemic Agents; p-values obtained from Chi square analysis. p-values <0.05 considered statistically significant

Table 3: Comparison of fasting and PP blood glucose levels between the study groups

| Duration        | Total study population (N=97) | Group 1 (N=32) | Group 2 (N=65) | p-value |
|-----------------|-------------------------------|----------------|----------------|---------|
| Fasting Blood   |                               |                |                |         |
| Glucose level   | Baseline                       | 155.0 (130.0-192.5) | 190.0 (159.25-276.75) | 144.0 (125.5-171.0) | <0.001 |
|                 | 2 weeks                        | 143.0 (121.0-185.0) | 163.5 (130.25-233.75) | 138.0 (118.5-166.5) | 0.20   |
|                 | 4 weeks                        | 135.0 (112.0-167.0) | 142.0 (120.0-193.75) | 133.0 (111.0-154.0) | 0.119  |
|                 | 6 weeks                        | 125.0 (107.0-156.0) | 126.5 (108.0-175.75) | 125.0 (106.0-148.0) | 0.773  |
| Post Prandial   |                               |                |                |         |
| Glucose level   | Baseline                       | 222.0 (177.5-306.5) | 295.0 (203.75-339.75) | 210.0 (170.0-275.0) | 0.002  |
|                 | 2 weeks                        | 222.0 (169.5-291.5) | 266.5 (195.25-308.75) | 197.0 (166.5-268.0) | 0.031  |
|                 | 4 weeks                        | 200.0 (156.5-269.0) | 235.0 (160.75-283.75) | 191.0 (154.5-261.0) | 0.388  |
|                 | 6 weeks                        | 195.0 (152.5-253.0) | 201.5 (140.25-260.0) | 193.0 (157.0-250.5) | 0.741  |

Values expressed in Median with 25th and 75th percentile given in parentheses. Mann Whitney U test was performed to compare mean ranks between Group 1 and Group 2. p-values <0.05 were considered statistically significant, and are expressed in bold typing.

92

ISSN 2091-2889 (Online) ISSN 2091-2412 (Print) JCMC/ Vol 10/ No. 4/ Issue 34/ Oct- Dec, 2020
We also compared whether a reduction in fasting and PP blood glucose levels was significant in subsequent weeks when compared to baseline values. Both groups had significantly lower blood glucose concentration (both fasting and PP) than baseline values after 2, 4, and 6 weeks of respective medications (Table 4).

### Table 5: Blood glucose levels of 2, 4, and 6 weeks compared to baseline values in group 1 and 2

| Blood glucose Levels (mg/dl) | Timeline | Median (25 -75 percentile) | p-value |
|-----------------------------|----------|-----------------------------|---------|
| Fasting - Group 1 (Antidiabetics + ESC) | Baseline | 190.0 (159.25-276.75) |  |
|                             | 2 weeks  | 163.5 (130.25-233.75) | <0.001 |
|                             | 4 weeks  | 142.0 (120.0-193.75) | <0.001 |
|                             | 6 weeks  | 126.5 (108.0-175.75) | <0.001 |
| Fasting - Group 2 (Antidiabetics) | Baseline | 144.0 (125.5-171.0) |  |
|                             | 2 weeks  | 138.0 (118.5-166.5) | 0.019  |
|                             | 4 weeks  | 133.0 (111.0-154.0) | 0.007  |
|                             | 6 weeks  | 125.0 (106.0-148.0) | 0.002  |
| Postprandial - Group 1 (Antidiabetics + ESC) | Baseline | 295.0 (203.75-339.75) |  |
|                             | 2 weeks  | 266.5 (195.25-308.75) | <0.001 |
|                             | 4 weeks  | 235.0 (160.75-283.75) | <0.001 |
|                             | 6 weeks  | 201.5 (140.25-260.0) | <0.001 |
| Postprandial - Group 2 (Antidiabetics) | Baseline | 210.0 (170.0-275.0) |  |
|                             | 2 weeks  | 197.0 (166.5-268.0) | <0.001 |
|                             | 4 weeks  | 191.0 (154.5-261.0) | <0.001 |
|                             | 6 weeks  | 193.0 (157.0-250.5) | <0.001 |

All the values were compared with baseline values. p-values were obtained from Wilcoxon Signed Rank test. p-values < 0.05 considered to be statistically significant, and are expressed in bold typing.

### DISCUSSION

This longitudinal study was conducted among 137 patients with type 2 diabetes mellitus under anti diabetic medications. The prevalence of depression among diabetic patients in the present study was 27%. Various other studies have reported a higher prevalence of depression in type 2 DM patients at 34%13, 39%14, and 34.4%.15 However, the relationship of diabetes and depression is unknown. The higher prevalence of depression in diabetic patients may be related to severe chronic illness, psychological factors associated with diabetes, and diabetic complications. Most of the diabetic patients with depression were females (27; 73%) and most of them are housewife (Table 1), in accordance with other studies.10,14 Majority (73%) of the depressed patients belonged to the age group 41-60 years. The mean ages from the other studies also fell within same age group.10,14 The reason for this is unclear and further study is required in future to rule out the cause of depression in diabetic patients.

In the present study, the baseline blood glucose levels (both fasting and PP) were higher in patients with diabetes and depression compared to patients with diabetes alone. A similar finding by De la Roca-Chiapas JM et al.16 and Groot et al.17 Lustman PJ et al. also have indicated that depression is associated with a patient with a higher blood glucose level. This may be due to poor adherence to diabetic medications, poor adherence to dietary habits, poor glycemic control and more diabetic complications. However, the exact mechanism is unknown.

Patients with chronic medical conditions, such as type 2 DM, are more likely to suffer from depression. Depression can interfere with self-care in diabetes and increase the risk of micro and macrovascular complications.14 The relation between depression and diabetes is still not clear as they seem to be intricately linked. Whatever be the causal association, the presence of one can significantly impact the other. Various studies have indicated that depression is associated with hyperglycemia.10,16,15 Depressed patients have poor glycemic control, despite medication, compared to the patients without any mood disorders like anxiety, depression etc.9,16 Depression is associated with increased activity of the hypothalamic-pituitary-adrenal axis and sympathetic nervous system resulting in increased release of cortisol, catecholamines, and glucagon. This results in increased glucose production, decreased insulin sensitivity, and reduced insulin secretion.19 Also, the patients with depression are less attentive towards a healthy lifestyle and increase the risk for type 2 DM. Similarly, the presence of depression in diabetic patients may be due to chronic anti diabetic treatment, diet restriction, increase financial burden, and various diabetes-related complications. Hypo or hyperglycemia induces negative emotional states in patients with diabetes resulting in depressive symptoms.18

In our study, we measured the fasting and PP blood glucose levels across various timelines (baseline, 2, 4, and 6 weeks). The baseline median blood glucose values in diabetic patients with depression were higher than diabetic patients without depression, as mentioned above. This suggests insufficient glycemic control in group 1 patients despite similar anti-diabetic treatment as the other group. After ESC treatment in this group, the difference in median blood glucose levels between the two groups diminished and was even comparable by the sixth week. Also, the reduction in blood glucose values was highly significant in both groups when compared with baseline values. While this reduction can be attributed to the ongoing anti-diabetic therapy in the patients without depression, the...
significant reduction in group 1 patients cannot be accredited solely to the anti-diabetic medications given the high baseline blood glucose values. A similar decrease in fasting and post-prandial blood sugar level was also found in the study done by Gehlawat et al 10 (p<0.05) and Dhavale et al 14 (FBGL p<0.029; PPBSL p=0.004). Another study done by Mathews J et al. 15 also found a statistically significant difference in fasting and post-prandial blood sugar level compared to baseline blood sugar levels after escitalopram treatment (p<0.05).

Whether the glycemic control achieved in group 1 patients after ESC treatment is simply due to the adequate management of the depression, an important type 2 DM risk factor, or due to specific glycemic control achieved by the drug cannot be hypothesized from this study. Various commonly used antidepressants, such as tricyclic antidepressants (TCAs), have shown to increase the risk for hyperglycemia. 16 The selective serotonin reuptake inhibitors (SSRIs) like ESC, on the other hand, have demonstrated favorable glycemic control effects in type 2 DM patients with depression on both short term and long term use. 14, 15, 20 It has been suggested that serotonergic activities of SSRIs result in increased insulin sensitivity and consequent reduction in blood sugar levels. Various studies have also shown that ESC treatment restores the hypothalamic-pituitary-adrenal axis and improved glucose uptake and insulin stimulation 21, reduce the risk of poor glycemic control 22 and have a synergistic effect on both mood and glycemic level in depressed diabetic patients. 23 Furthermore, ESC is a new SSRI with better-tolerated side effects in elderly patients and also has a rapid onset of action (1-2 weeks). These properties have made ESC the most prescribed antidepressant medication in depressed patients with diabetes. 24 The findings from our study also favor the use of this drug in depressed diabetic patients to achieve the desired glycemic control, in addition to antidiabetic medications. However, larger studies with proper assessment of comorbid conditions and other confounders are recommended for validation.

This is a single-center study with a small number of patients, so results could not be generalized. There is a need for further multicenter studies for establishing effective treatment options for the patients of comorbid diabetes and depression. The effects of comorbid conditions on glycemic control, as well as depression, were not evaluated. Thus, large studies should be done to find out the depression in type 2 diabetes patients and their comorbid complications. More studies are required to compare the role of antidepressants in treating depression in diabetic patients.

CONCLUSION

This study suggests that depression is common in patients with type 2 DM. Thus, the assessment of depression should be done in patients with type 2 DM. The present study showed a significant reduction in fasting and post-prandial blood glucose level from baseline to six weeks after the treatment with Escitalopram in patients with diabetes mellitus and depression. Thus, Escitalopram can be considered as an efficacious drug for treating depression in patients suffering from type 2 diabetes mellitus. Further large-scale studies, including comparison with other antidepressants, are recommended.

ACKNOWLEDGEMENT

We greatly acknowledge Dr. Prabin Khatri for his cooperation in this study. We express our gratitude to Dr. Navin Patil for his guidance and constructive feedback and suggestions. We also express a heartfelt thanks to all the participants of the study.

CONFLICT OF INTEREST: None

FINANCIAL DISCLOSURE: None

REFERENCES:

1. Joshi B, Shrestha L, Bhattarai K, Manandhar N, Mahotra NB. Comparison of central obesity with overall obesity in predicting the risk of type 2 diabetes mellitus. Journal of Universal College of Medical Sciences. 2019;7(1):17-21. [DOI]

2. Iglay K, Hannachi H, Joseph Howie P, et al. Prevalence and co-prevalence of comorbidities among patients with type 2 diabetes mellitus. Current medical research and opinion. 2016;32(7):1243-52. [DOI]

3. Anderson RJ, Freedland KE, Clouse RE, Lustman PJ. The prevalence of comorbidity depression in adults with diabetes: a meta-analysis. Diabetes care. 2001;24(6):1069-78. [DOI]

4. Ali S, Stone M, Peters J, Davies M, Khunti K. The prevalence of co-morbid depression in adults with Type 2 diabetes: a systematic review and meta-analysis. Diabetic medicine. 2006;23(11):1165-73. [DOI]

5. Mut-Vitcu G, Timar B, Timar R, Oancea C, Citu IC. Depression influences the quality of diabetes-related self-management activities in elderly patients with type 2 diabetes: a cross-sectional study. Clinical interventions in aging. 2016;11:471. [DOI]

6. Kaur G, Tee GH, Aariatnam S, Krishnapillai AS, China K. Depression, anxiety and stress symptoms among diabetics in Malaysia: a cross sectional study in an urban primary care setting. BMC family practice. 2013;14(1):69. [DOI]

7. Mathew M, Abish A, Kuriakose A, Isiah JR, Kiran A, Vijayakumar K. Predictors of depression among patients with diabetes mellitus in Southern India. Asian journal of psychiatry. 2013;6(4):313-7. [DOI]

8. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes care. 2004;27(5):1047-53. [DOI]

9. De Groot M, Kushnick M, Doyle T, et al. Depression among adults with diabetes: prevalence, impact, and treatment options. Diabetes Spectrum. 2010;23(1):15-8. [DOI]

10. Kumar K, Salman M, Shukla V, et al. Comparative Effect of Agomelatine versus Escitalopram on Glycemic Control and Symptoms of Depression in Patients with Type 2 Diabetes Mellitus and Depression. JPSR. 2015;6(10):4304-9. [DOI]

11. Gehlawat P, Gupta R, Rajput R, Gahian D, Gehlawat VK. Diabetes with co-morbid depression: role of SSRI in better glycemic control. Asian journal of psychiatry. 2013;6(5):364-8. [DOI]

12. Gyawali B, Hansen MRH, Povlsen MB, et al. Awareness, prevalence, treat-
ment, and control of type 2 diabetes in a semi-urban area of Nepal: Findings from a cross-sectional study conducted as a part of COBIN-D trial. PloS one. 2018;13(11):e0206491. [DOI]
13. Pahari DP, Upadhay R, Sharma CK. Depression among diabetic patients visiting a diabetes center in Nepal. Health Prospect: Journal of Public Health. 2018;17(1):21-5. [DOI]
14. Dhavale H, Panikkar V, Jadhav BS, Ghulghule M, Agari A. Depression and diabetes: impact of antidepressant medications on glycaemic control. J Assoc Physicians India. 2013;61(12):896-9. [PMID]
15. Mathews J, Dange SV, Dutta A, Tilak AV, Shende SS, Das S. An observational study of the effect of escitalopram and etizolam in type 2 diabetes mellitus patients with depression. International Journal of Basic & Clinical Pharmacology. 2016;5(5):1. [DOI]
16. De la Roca-Chiapas JM, Hernández-González M, Candelario M, et al. Association between depression and higher glucose levels in middle-aged Mexican patients with diabetes. Rev Invest Clin. 2013;65(3):209-13. [LINK]
17. Elwing JE, Lustman PJ, Wang HL, Clouse RE. Depression, anxiety, and non-alcoholic steatohepatitis. Psychosomatic medicine. 2006;68(4):563-9. [DOI]
18. Siddiqui S. Depression in type 2 diabetes mellitus—a brief review. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2014;8(1):62-5. [DOI]
19. Tabák AG, Akbaraly TN, Batty GD, Kivimäki M. Depression and type 2 diabetes: a causal association? The lancet Diabetes & endocrinology. 2014;2(3):236-45. [DOI]
20. Deuschle M. Effects of antidepressants on glucose metabolism and diabetes mellitus type 2 in adults. Current opinion in psychiatry. 2013;26(1):60-5. [DOI]
21. Buhl ES, Jensen TK, Jessen N, et al. Treatment with an SSRI antidepressant restores hippocampo-hypothalamic corticosteroid feedback and reverses insulin resistance in low-birth-weight rats. American Journal of Physiology-Endocrinology and Metabolism. 2010;298(5):E920-E929. [DOI]
22. Gagnon J, Lussier M-T, MacGibbon B, Daskalopoulou SS, Bartlett G. The impact of antidepressant therapy on glycemic control in Canadian primary care patients with diabetes mellitus. Frontiers in nutrition. 2018;5:47. [DOI]
23. Markowitz SM, Gonzalez JS, Wilkinson JL, Safren SA. A review of treating depression in diabetes: emerging findings. Psychosomatics. 2011;52(1):1-18. [DOI]